Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq:MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the third quarter of 2023.
Related news for (MTEM)
- Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
- Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
- Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169